Literature DB >> 29359672

Is there Sex-related Outcome Difference According to oral P2Y12 Inhibitors in Patients with Acute Coronary Syndromes? A Systematic Review and Meta-Analysis of 107,126 Patients.

Oliver Brown1, Jennifer Rossington1, Gill Louise Buchanan2, Giuseppe Patti3, Angela Hoye1.   

Abstract

BACKGROUND AND OBJECTIVES: The majority of patients included in trials of anti-platelet therapy are male. This systematic review and meta-analysis aimed to determine whether, in addition to aspirin, P2Y12 blockade is beneficial in both women and men with acute coronary syndromes.
METHODS: Electronic databases were searched and nine eligible randomised controlled studies were identified that had sex-specific clinical outcomes (n=107,126 patients). Risk Ratios (RR) and 95% Confidence Intervals (CI) were calculated for a composite of cardiovascular death, myocardial infarction or stroke (MACE), and a safety endpoint of major bleeding for each sex. Indirect comparison analysis was performed to statistically compare ticagrelor against prasugrel.
RESULTS: Compared to aspirin alone, clopidogrel reduced MACE in men (RR, 0.79; 95% CI, 0.68 to 0.92; p=0.003), but was not statistically significant in women (RR, 0.88; 95% CI, 0.75 to 1.02, p=0.08). Clopidogrel therapy significantly increased bleeding in women but not men. Compared to clopidogrel, prasugrel was beneficial in men (RR, 0.84; 95% CI, 0.73 to 0.97; p=0.02) but not statistically significant in women (RR, 0.94; 95% CI, 0.83 to 1.06; p=0.30); ticagrelor reduced MACE in both men (RR, 0.85; 95% CI, 0.77 to 0.94; p=0.001) and women (RR, 0.84; 95% CI, 0.73 to 0.97; p=0.02). Indirect comparison demonstrated no significant difference between ticagrelor and prasugrel in either sex. Compared to clopidogrel, ticagrelor and prasugrel increased bleeding risk in both women and men.
CONCLUSION: In summary, in comparison to monotherapy with aspirin, P2Y12 inhibitors reduce MACE in women and men. Ticagrelor was shown to be superior to clopidogrel in both sexes. Prasugrel showed a statistically significant benefit only in men; however indirect comparison did not demonstrate superiority of ticagrelor over prasugrel in women. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  ACS; CHD; MACE; P2Y12; Sex; inhibitors; oral.

Mesh:

Substances:

Year:  2019        PMID: 29359672     DOI: 10.2174/1570161116666180123092054

Source DB:  PubMed          Journal:  Curr Vasc Pharmacol        ISSN: 1570-1611            Impact factor:   2.719


  1 in total

1.  Efficacy and Safety of Ticagrelor Versus Prasugrel in Women and Men with Acute Coronary Syndrome: A Pre-specified, Sex-Specific Analysis of the ISAR-REACT 5 Trial.

Authors:  Senta Gewalt; Shqipdona Lahu; Gjin Ndrepepa; Costanza Pellegrini; Isabell Bernlochner; Franz-Josef Neumann; Maurizio Menichelli; Tanja Morath; Bernhard Witzenbichler; Jochen Wöhrle; Katharina Hoppe; Gert Richardt; Karl-Ludwig Laugwitz; Heribert Schunkert; Adnan Kastrati; Stefanie Schüpke; Katharina Mayer
Journal:  J Atheroscler Thromb       Date:  2021-04-16       Impact factor: 4.394

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.